FDA Ends Ozempic, Wegovy Shortage; Compounding Impact

The FDA announced the end of the shortage of Novo Nordisk's semaglutide medications, Ozempic and Wegovy, which are used for diabetes and weight loss. Novo Nordisk has ramped up production to meet the high demand, investing significantly in expanding their manufacturing capabilities. With the shortage resolved, compounding pharmacies will no longer be able to produce cheaper, unapproved versions of these drugs after a grace period, potentially impacting patients who relied on more affordable options. Despite the resolution, intermittent supply disruptions may still occur as products move through the supply chain. This decision follows a similar resolution for Eli Lilly's tirzepatide-based drugs, Mounjaro and Zepbound. The end of the shortage reflects the broader pharmaceutical strategy to regain market control from compounding pharmacies, which had filled the gap during the shortage period.